Better therapies for patients
We make a difference in people´s health - and in your portfolio
Grow your brand with added value and innovative medicines for patients!
Whether it´s fewer side effects, a better API absorption or a personalized drug dispensing device, we at AET believe that there are always new ways of smart medicines which better deliver on patients´ needs. Our highly experienced research & development and innovation managers continuously strive for new pharmaceutical technologies and products – both in the field of generics and innovative formulations. This pioneer spirit is driven by our curiosity – the curiosity of each of our employees dedicated to make patients´ life better. To better understand patients´ needs, our experts are in close and regular collaboration with universities and key opinion leaders of all relevant disciplines.
Our own laboratories with up-to-date technologies and our exclusive global network of development partners enable us to cover all major therapeutics as well as diverse and innovative dosage forms. We succeed in developing tablets, capsules, modified release formulations, oral and ophthalmic solutions as well as special technologies like patches, inhalers, injectables or personalized devices. Furthermore, we are committed to drive for growth and innovation with a well-defined and specialized portfolio of highly potent drug formulations. Our current portfolio consists of 180 products: 100 dossiers, 40 products under development and 40 in our pipeline. Every year, we start the development of 10 to 15 promising new products – both niche products and blockbusters – to fuel our sustainable growth. Outstanding intellectual property guidance and quality assurance are the backbone of our research & development operations.
How we drive better therapies for patients
Our success factors for breakthrough research and development
We focus on discovering value added and innovative drugs that can change the practices of medicine by using groundbreaking science and technology. Our capabilities span a wide range of development technologies and specialties—all backed by comprehensive industry knowledge and experience.
pioneer spirit and patient-focused development approach
close collaborations with universities and key opinion leaders of several indications
more than 100 products successfully developed
40 products under development and 40 in pipeline incl. highly potent drugs
pioneer spirit and patient focused development approach
close collaborations with universities and key opinion leaders of several indications
more than 100 products successfully developed
40 products under development and 40 in pipeline
special technologies and outstanding quality assurance
global IP clearance, protection, and filing
above-average success in BE and clinical studies
FDA, MIT and BGV approved own laboratories
special technologies and outstanding quality assurance
global IP clearance, protection, and filing
above-average success in BE and clinical studies
FDA, MIT and BGV approved own laboratories
Creating better therapies through product differentiation and innovation
Value added and innovative medicines which will set you apart
Product differentiation and innovation are a core business at TIEFENBACHER PHARMACEUTICALS. We believe that there are always new ways of smart medicines which better deliver on patients` needs. This includes less side effects, a better API absorption, additional product strengths, new fix-dose combinations, or a personalized dosing with an innovative drug device – just to name a few examples of our distinctive product features and innovations. We are constantly developing new product solutions for reaching an unique selling proposition in the market and bringing added value to patients – always with a patient-centric approach.
Value added Products
Innovative Products
- Once-daily products for better posology
- More patient-friendly dosage forms than the innovator
- Prodrugs with better side-effect profile (e.g. to make MS therapy safer)
- Prodrug with 5 years of IP advantage
- Extended-release formulations with less side effects
- New suitable dosage strengths for better treatment options
- Fix-dose combinations
- Digital platform for new drug /device combination for personalized treatment
- New orphan indication for known molecule
- New OTC products
- First NCE-approved drug in Europe
This is a selection of our development pipeline. We provide over 180+ products across various therapeutic categories in 10+ dosage forms – and additional medical devices and drug device combinations. We are not limited to specific disease areas – whether for widespread or for orphan diseases. Furthermore, we are committed for growth and innovation by offering a well-defined and specialized portfolio of highly potent drugs.
For more information about our differentiated and innovative product pipeline, please contact us – by filling out the contact form below on this webpage, or please send an email to info@aet.eu. We are looking forward to share these licensing opportunities based on a CDA and the specific marketing & sales requirements.
Differentiated Products
- Once-daily products for better posology
- More patient-friendly dosage form than the innovator
- Prodrugs with better side-effect profile (e.g. to make MS therapy safer)
- Prodrug with 5 years of IP advantage
- Extended-release formulations with less side effects
- New suitable dosage strengths for better treatment options
- Fix-dose combinations
Innovative Products
- Innovative vaginitis product
- Digital platform for new drug /device combination for personalized treatment
- New orphan indication for known molecule
- New OTC products
- First NCE approved drug in Europe
TIEFENBACHER Laboratories - With advanced technologies to pharmaceuticals of the future
Our FDA approved laboratories in India
The research and development operations for both generic and innovative formulations are supported by our advanced laboratory in Hyderabad, India. TIEFENBACHER LABORATORIES features a GLP/GMP compliant environment on a 32.000 m² sized plant. Most modern techniques and softwares (e. g. inhouse XRD Crystallography, WinNonlin IVIVC simulation tools, Nitrosamine testing, Malvern particle size testing) are part of the state-of-the-art research & development equipment. With our new own high potent lab we are committed to drive for growth and innovation and are able to develop a well-defined and specialized portfolio of highly potent drug formulations inhouse. This includes the development of tablets as well as capsules.
Quality control is an integral part of TIEFENBACHER LABORATORIES. It ensures a development process which considers all aspects of quality requirements, customer requirements, transparency, and applying good manufacturing practice – according to national as well as international legislation. The development projects are performed following ICH, EU, USFDA and other international guidelines. This enables us to generate a corresponding documentation for the submission of a marketing authorization application in the EU, in the US, and further international territories. TIEFENBACHER LABORATORIES holds the ISO 14001:2014 and ISO 18001:2015 certifications and was successfully inspected by the German BGV, the US FDA authorities, the Russian MIT, and the Turkish Ministry of Health.
We are experts and innovators to improve people’s life
New Generation of pharmaceuticals: our new state-of-the-art facility for highly potent drugs
TIEFENBACHER PHARMACEUTICALS is now able to develop and manufacture highly potent drugs in its new dedicated site in Hyderabad, India. Our competence ranges from the first phase of research to the commercial production of drugs for the treatment of cancer and other conditions – for both tablets and capsules.
The new state-of-the-art lab is equipped with the most modern techniques and software and will be supplemented by a new manufacturing block with special technologies in 2023. The whole complex will cover a total of about 4.000 square meters. TIEFENBACHER PHARMACEUTICALS has already 25 leading highly potent drugs in its launch pipeline which are planned to be developed and produced in-house in the new facilities in Hyderabad. While the operational start of the lab has already started (including small-scale production), the commercial production for larger quantities in the new manufacturing block is expected for 2024.
For more information about our highly potent drug competence and innovative science and technologies, please contact us at any stage of your inquiry – by filling out the contact form below on this webpage, or please directly send an email to info@aet.eu
We are best practice
First NCE approval for innovative sleeping medicine
In 2019 AET successfully gained the first European NCE approval for an advanced drug being used to treat the symptoms of insomnia in a better and safer way. Studies have shown that our sleeping aid has the following main advantages compared to other sedative drugs: Our product has a lower dosage and, based on available studies, can be used for a longer period of time. Other sleeping pills may only be used for a maximum of two weeks. The innovative drug has been studied in a variety of clinical settings involving primary insomnia and insomnia secondary to various chronic conditions such as rheumatoid arthritis, generalised anxiety disorder, and major depressive illness. The results across studies in adults are consistent and demonstrate shorter sleep latency, longer sleep time, and less wakening after the onset of sleep compared to placebo. Furthermore, the study program revealed that our sleeping medicine provides safety benefits resulting from lower morning serum levels.
The product will be launched in 2021 in several European countries. With this first marketing authorization, AET enables thousands of patients in Europe suffering from insomnia a better and safer therapy – sustainably improving their quality of life.
Tiefenbacher Pharmaceuticals is driving better therapies for patients by developing high-quality medicines
We, at TIEFENBACHER PHARMACEUTICALS, are making medicines more affordable, more available, and better than before. Do not hesitate to get in touch for more information on our differentiated and innovative product pipeline.Please contact us by filling out the contact form below and clicking “Send message”. TIEFENBACHER PHARMACEUTICALS will follow up with you personally as soon as possible.
